Therapeutic profile of patients with diabetes treated at the first level of health care
- Autores
- Maidana, Gladys Mabel; Marin, Gustavo Horacio; Samaniego, Lourdes; Marin, Lupe; Montiel, Dalva Fariña; Marin, Gina; Vera, Zully; Lugo Rodríguez, Gladys B.
- Año de publicación
- 2020
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Introduction: Diabetes mellitus type 2 (DM2) is a chronic metabolic disease frequently associated with late complications derived from progressive damage several tissues. When patients with DM2 do not respond adequately to non-pharmacological measures, anti-diabetic agents should be indicated to avoid the long-term risk of macro and microvascular complications. Objective: The aim of this study is to evaluate the therapeutic profile for DM2 in the first level of care in the health system in two different countries (Argentina and Paraguay). Methods: This study was an observational descriptive cross-section study. Variables considered were age, sex, date of disease debut, clinical signs of diabetes complications, blood pressure, abdominal circumference, anti-diabetic and anti-hypertensive drugs, and laboratory data. Results: Regarding medication, 30.6% of the patients were treated with biguanides (metformin) and 23.5% with oral hypoglycemic agents; 21.7% with a combination of both anti-diabetic groups; and 3.5% with other therapeutically options (glitazones, meglitinides, SGLT2 inhibitors, and GLP-1 agonist). All the cases of new drug indications were register in Argentina while in Paraguay; all drugs prescribed were considered essential medicines. Conclusion: Diabetes is a frequent disease that causes severe disabilities and death in the affected population. Although it exists several drugs for DM2 treatment, only a few of them follow the rational use of medicines guidelines, while other drugs might be unsafe and certainly more expensive than essential options. Since first level health-care therapeutic strategy plays a major role in avoiding complications from diabetes, countries with low or middle income such as Paraguay or Argentina should do efforts to provide to all patients a rational treatment. This work shows that not in all scenarios, this pattern is true.
Fil: Maidana, Gladys Mabel. Universidad Nacional de Asunción; Paraguay
Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; Argentina
Fil: Samaniego, Lourdes. Universidad Nacional de Asunción; Paraguay
Fil: Marin, Lupe. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; Argentina
Fil: Montiel, Dalva Fariña. Universidad Nacional de Asunción; Paraguay
Fil: Marin, Gina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; Argentina
Fil: Vera, Zully. Universidad Nacional de Asunción; Paraguay
Fil: Lugo Rodríguez, Gladys B.. Universidad Nacional de Asunción; Paraguay - Materia
-
DIABETES
FIRST LEVEL
HEALTH CARE
TREATMENT - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/144918
Ver los metadatos del registro completo
id |
CONICETDig_311101495662d2c2af42c9d3bf8d9b1f |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/144918 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Therapeutic profile of patients with diabetes treated at the first level of health careMaidana, Gladys MabelMarin, Gustavo HoracioSamaniego, LourdesMarin, LupeMontiel, Dalva FariñaMarin, GinaVera, ZullyLugo Rodríguez, Gladys B.DIABETESFIRST LEVELHEALTH CARETREATMENThttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Introduction: Diabetes mellitus type 2 (DM2) is a chronic metabolic disease frequently associated with late complications derived from progressive damage several tissues. When patients with DM2 do not respond adequately to non-pharmacological measures, anti-diabetic agents should be indicated to avoid the long-term risk of macro and microvascular complications. Objective: The aim of this study is to evaluate the therapeutic profile for DM2 in the first level of care in the health system in two different countries (Argentina and Paraguay). Methods: This study was an observational descriptive cross-section study. Variables considered were age, sex, date of disease debut, clinical signs of diabetes complications, blood pressure, abdominal circumference, anti-diabetic and anti-hypertensive drugs, and laboratory data. Results: Regarding medication, 30.6% of the patients were treated with biguanides (metformin) and 23.5% with oral hypoglycemic agents; 21.7% with a combination of both anti-diabetic groups; and 3.5% with other therapeutically options (glitazones, meglitinides, SGLT2 inhibitors, and GLP-1 agonist). All the cases of new drug indications were register in Argentina while in Paraguay; all drugs prescribed were considered essential medicines. Conclusion: Diabetes is a frequent disease that causes severe disabilities and death in the affected population. Although it exists several drugs for DM2 treatment, only a few of them follow the rational use of medicines guidelines, while other drugs might be unsafe and certainly more expensive than essential options. Since first level health-care therapeutic strategy plays a major role in avoiding complications from diabetes, countries with low or middle income such as Paraguay or Argentina should do efforts to provide to all patients a rational treatment. This work shows that not in all scenarios, this pattern is true.Fil: Maidana, Gladys Mabel. Universidad Nacional de Asunción; ParaguayFil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; ArgentinaFil: Samaniego, Lourdes. Universidad Nacional de Asunción; ParaguayFil: Marin, Lupe. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; ArgentinaFil: Montiel, Dalva Fariña. Universidad Nacional de Asunción; ParaguayFil: Marin, Gina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; ArgentinaFil: Vera, Zully. Universidad Nacional de Asunción; ParaguayFil: Lugo Rodríguez, Gladys B.. Universidad Nacional de Asunción; ParaguayAsclepius2020-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/144918Maidana, Gladys Mabel; Marin, Gustavo Horacio; Samaniego, Lourdes; Marin, Lupe; Montiel, Dalva Fariña; et al.; Therapeutic profile of patients with diabetes treated at the first level of health care; Asclepius; Asclepius Medical Research and Reviews; 3; 2; 8-2020; 1-52639-8605CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://asclepiusopen.com/asclepius-medical-research-and-reviews/volume-3-issue-2/1info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:02:19Zoai:ri.conicet.gov.ar:11336/144918instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:02:20.141CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Therapeutic profile of patients with diabetes treated at the first level of health care |
title |
Therapeutic profile of patients with diabetes treated at the first level of health care |
spellingShingle |
Therapeutic profile of patients with diabetes treated at the first level of health care Maidana, Gladys Mabel DIABETES FIRST LEVEL HEALTH CARE TREATMENT |
title_short |
Therapeutic profile of patients with diabetes treated at the first level of health care |
title_full |
Therapeutic profile of patients with diabetes treated at the first level of health care |
title_fullStr |
Therapeutic profile of patients with diabetes treated at the first level of health care |
title_full_unstemmed |
Therapeutic profile of patients with diabetes treated at the first level of health care |
title_sort |
Therapeutic profile of patients with diabetes treated at the first level of health care |
dc.creator.none.fl_str_mv |
Maidana, Gladys Mabel Marin, Gustavo Horacio Samaniego, Lourdes Marin, Lupe Montiel, Dalva Fariña Marin, Gina Vera, Zully Lugo Rodríguez, Gladys B. |
author |
Maidana, Gladys Mabel |
author_facet |
Maidana, Gladys Mabel Marin, Gustavo Horacio Samaniego, Lourdes Marin, Lupe Montiel, Dalva Fariña Marin, Gina Vera, Zully Lugo Rodríguez, Gladys B. |
author_role |
author |
author2 |
Marin, Gustavo Horacio Samaniego, Lourdes Marin, Lupe Montiel, Dalva Fariña Marin, Gina Vera, Zully Lugo Rodríguez, Gladys B. |
author2_role |
author author author author author author author |
dc.subject.none.fl_str_mv |
DIABETES FIRST LEVEL HEALTH CARE TREATMENT |
topic |
DIABETES FIRST LEVEL HEALTH CARE TREATMENT |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Introduction: Diabetes mellitus type 2 (DM2) is a chronic metabolic disease frequently associated with late complications derived from progressive damage several tissues. When patients with DM2 do not respond adequately to non-pharmacological measures, anti-diabetic agents should be indicated to avoid the long-term risk of macro and microvascular complications. Objective: The aim of this study is to evaluate the therapeutic profile for DM2 in the first level of care in the health system in two different countries (Argentina and Paraguay). Methods: This study was an observational descriptive cross-section study. Variables considered were age, sex, date of disease debut, clinical signs of diabetes complications, blood pressure, abdominal circumference, anti-diabetic and anti-hypertensive drugs, and laboratory data. Results: Regarding medication, 30.6% of the patients were treated with biguanides (metformin) and 23.5% with oral hypoglycemic agents; 21.7% with a combination of both anti-diabetic groups; and 3.5% with other therapeutically options (glitazones, meglitinides, SGLT2 inhibitors, and GLP-1 agonist). All the cases of new drug indications were register in Argentina while in Paraguay; all drugs prescribed were considered essential medicines. Conclusion: Diabetes is a frequent disease that causes severe disabilities and death in the affected population. Although it exists several drugs for DM2 treatment, only a few of them follow the rational use of medicines guidelines, while other drugs might be unsafe and certainly more expensive than essential options. Since first level health-care therapeutic strategy plays a major role in avoiding complications from diabetes, countries with low or middle income such as Paraguay or Argentina should do efforts to provide to all patients a rational treatment. This work shows that not in all scenarios, this pattern is true. Fil: Maidana, Gladys Mabel. Universidad Nacional de Asunción; Paraguay Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; Argentina Fil: Samaniego, Lourdes. Universidad Nacional de Asunción; Paraguay Fil: Marin, Lupe. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; Argentina Fil: Montiel, Dalva Fariña. Universidad Nacional de Asunción; Paraguay Fil: Marin, Gina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; Argentina Fil: Vera, Zully. Universidad Nacional de Asunción; Paraguay Fil: Lugo Rodríguez, Gladys B.. Universidad Nacional de Asunción; Paraguay |
description |
Introduction: Diabetes mellitus type 2 (DM2) is a chronic metabolic disease frequently associated with late complications derived from progressive damage several tissues. When patients with DM2 do not respond adequately to non-pharmacological measures, anti-diabetic agents should be indicated to avoid the long-term risk of macro and microvascular complications. Objective: The aim of this study is to evaluate the therapeutic profile for DM2 in the first level of care in the health system in two different countries (Argentina and Paraguay). Methods: This study was an observational descriptive cross-section study. Variables considered were age, sex, date of disease debut, clinical signs of diabetes complications, blood pressure, abdominal circumference, anti-diabetic and anti-hypertensive drugs, and laboratory data. Results: Regarding medication, 30.6% of the patients were treated with biguanides (metformin) and 23.5% with oral hypoglycemic agents; 21.7% with a combination of both anti-diabetic groups; and 3.5% with other therapeutically options (glitazones, meglitinides, SGLT2 inhibitors, and GLP-1 agonist). All the cases of new drug indications were register in Argentina while in Paraguay; all drugs prescribed were considered essential medicines. Conclusion: Diabetes is a frequent disease that causes severe disabilities and death in the affected population. Although it exists several drugs for DM2 treatment, only a few of them follow the rational use of medicines guidelines, while other drugs might be unsafe and certainly more expensive than essential options. Since first level health-care therapeutic strategy plays a major role in avoiding complications from diabetes, countries with low or middle income such as Paraguay or Argentina should do efforts to provide to all patients a rational treatment. This work shows that not in all scenarios, this pattern is true. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-08 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/144918 Maidana, Gladys Mabel; Marin, Gustavo Horacio; Samaniego, Lourdes; Marin, Lupe; Montiel, Dalva Fariña; et al.; Therapeutic profile of patients with diabetes treated at the first level of health care; Asclepius; Asclepius Medical Research and Reviews; 3; 2; 8-2020; 1-5 2639-8605 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/144918 |
identifier_str_mv |
Maidana, Gladys Mabel; Marin, Gustavo Horacio; Samaniego, Lourdes; Marin, Lupe; Montiel, Dalva Fariña; et al.; Therapeutic profile of patients with diabetes treated at the first level of health care; Asclepius; Asclepius Medical Research and Reviews; 3; 2; 8-2020; 1-5 2639-8605 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://asclepiusopen.com/asclepius-medical-research-and-reviews/volume-3-issue-2/1 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Asclepius |
publisher.none.fl_str_mv |
Asclepius |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269751686987776 |
score |
13.13397 |